Elsa Renee Flores
@LabElsaFlores
Followers
742
Following
3K
Media
45
Statuses
543
Moffitt Cancer Center ACD & Division Chief, Basic Science. Cancer Biologist. Discovery Science.
Tampa, FL
Joined February 2020
At #SITC25, Kenneth Tsai, MD (@KYTsaiLab), presents Phase II results showing a 57.7% pCR with neoadjuvant lenvatinib plus pembrolizumab in stage II–IV Merkel cell carcinoma. Responders show interferon and ANGPTL1 signaling; nonresponders show neural and E2F/MYC pathways with
0
3
7
Highlights from the Jaeger Lab at SITC!
Tomorrow at #SITC25, Christopher Polera will share research on how RAS inhibition reshapes the tumor immunopeptidome to reveal new immunogenic targets and inform combination immunotherapy strategies. #MoffittSITC25 @sitcancer
0
0
2
Great Moffitt basic science at SITC!
At #SITC25, Alex Jaeger, PhD joins Greg Sawyer, PhD (@ProfGregSawyer) to discuss the work his lab is presenting, including the immunopeptidome, MHC-I and MHC-II. #MoffittSITC25
0
2
6
Live from #SITC25: Kenneth Tsai, MD (@KYTsaiLab) presents data showing that Pembrolizumab plus Levatinib demonstrated encouraging efficacy as neoadjuvant therapy for resectable clinical stage II-IV Merkel cell carcinoma.
0
5
9
Tomorrow at #SITC25: Kenneth Tsai, MD, PhD (@KYTsaiLab) presents a late-breaking abstract on the molecular and immunologic correlates of response in the phase II study of neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma. #MoffittSITC25 @sitcancer
0
6
9
Excited to share our new paper in @PNAS! We developed biodegradable biomaterials that organize immune cells into tertiary lymphoid–like structures, potentially improving outcomes for patients less responsive to immunotherapies. @DrJamesMule @MoffittNews
https://t.co/UVVjspTJml
1
1
8
#ScienceSaturday ❓ Some people with multiple myeloma respond well to CAR T-cell therapy, but others relapse when the cancer finds ways to hide. Why does that happen, and how can we fix it? ➡️ Dr. Fabiana Perna and colleagues at Moffitt Cancer Center, found that one reason is
5
14
89
Congratulations @LabKissil ! Exciting new model of lung cancer! @MoffittNews @PatrickHwuMD @KYTsaiLab
⭐️The first genetically engineered endogenous cancer model in naked mole-rats 👇
0
1
9
Moffitt Study Uncovers New Mechanism of Immunotherapy Resistance | Moffitt https://t.co/1nI0HC2cqN Exciting research from the Tsai lab published in Nature!
moffitt.org
Cancer-induced nerve injury weakens anti-PD-1 treatment, but novel approaches may overcome it
0
6
23
So pleased to see this important work published. Congrats in particular to @moranamit2 for this massive effort detailing how cancers cause nerve injury, which in turn leads to an immunosuppressive environment driving immunotherapy resistance.
nature.com
Nature - Perineural invasion and cancer-induced nerve injury of tumour-associated nerves are associated with poor response to anti-PD-1 therapy, which can be reversed by combining anti-PD-1 therapy...
1
3
10
Super excited to share our newest piece out today @NatureRevCancer linking age-induced metabolic reprogramming to cancer development.
nature.com
Nature Reviews Cancer - In this Perspective, Lazure and Gomes argue that metabolic changes that occur as a result of ageing may shape tumour initiation and progression and the development of...
11
47
239
So exciting to be an integral part of the project! Can’t wait to tour the Moffitt Discovery & Innovation Center with you when we are open for science!@PatrickHwuMD @MoffittNews COO Sabi Singh @Timadams2023 @LeeMoffitt
Today I toured our #SperosFL campus under construction in Pasco County alongside @MoffittNews COO Sabi Singh and Board Chair Tim Adams. Incredible to see the progress and vision coming to life, from the Discovery & Innovation Center to the Speros Outpatient Center and the Richard
0
2
13
Fabulous and inspiring scientist and mentor @DrJamesMule !
🚨 New episode of #TheImmunoVerse podcast is live! I had the honor of speaking with @DrJamesMule, a true pioneer in cell therapy and cancer immunology @MoffittNews. In this episode, he talks about carrying immunotherapy, particularly T cell therapy, from skepticism to standard
0
0
10
I had the privilege of showing off the progress of the Moffitt Discovery and Innovation Center at SPEROS FL to a group of pioneering faculty. It’s been a real labor of love! Thank you to TKD, Whiting Turner, and Hammes for bringing the vision to life! Can’t wait to make new
0
4
28
🚨Breaking Science from #ASCO25. Kenneth Tsai, MD, PhD, (@KYTsaiLab) joined us to discuss new data from the C-POST trial on adjuvant cemiplimab for patients with high-risk cutaneous squamous cell carcinoma. Details ⬇️ Read more: https://t.co/ovURg1DWre
#MoffittASCO25 @ASCO
1
10
26
Live from #ASCO25, Eric Haura, MD joined me at the @MoffittNews booth to discuss what he's most excited about at this year's annual meeting, including the evolution of RAS inhibitors—a class of targeted therapies designed to block the activity of RAS proteins, which are among the
0
7
15
Exciting times for Moffitt and our Discovery and Innovation Center opening June 2026! Honored to be leading this effort for the SPEROS FL biotech hub!
The newly appointed president of Speros discusses strategies for uniting clinical expertise, research and commercial interests at Moffitt's expansive new campus.
0
1
8
Last night at #ASCO25, we celebrated the outstanding work of our Moffitt researchers and connected with industry partners driving progress in cancer research and care. Thank you to everyone who joined us! Together, we are contributing to the prevention and cure of cancer!
0
11
25
Promotion and tenure season has started! First up - Dr. Inna Smalley shared her beautiful body of work on leptomeningeal disease. @MoffittNews @PatrickHwuMD
1
1
19